Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.84%. A quarter ago, it was expected that this company would post a loss of $7.5 per share when it actually produced a loss of $6, delivering a surprise of +20%.Over the last four quarters, the company has surp ...